Welcome to our dedicated page for Mimedx Group news (Ticker: MDXG), a resource for investors and traders seeking the latest updates and insights on Mimedx Group stock.
MiMedx Group, Inc. develops and commercializes regenerative biomaterial products for wound care, burn and surgical applications. Its updates center on placental allografts and related advanced wound care technologies, including AMNIOFIX, CHORIOFIX and G4Derm Plus, as the company adds product configurations, distribution rights and clinical evidence for complex wound management.
Company news also covers operating results for the Wound and Surgical businesses, reimbursement-driven market conditions, cost-reduction actions, investor presentations, conference participation and capital actions such as share repurchase authorization.
MiMedx Group, Inc. (NASDAQ: MDXG) announced its participation in the Symposium on Advanced Wound Care Fall, taking place from November 4-6. The company will showcase its new EpiCord Expandable allograft, which can expand to twice its size, enhancing treatment for chronic wounds. Experts will discuss the quality of clinical trials in wound care, emphasizing bias in study designs. MiMedx has processed over two million allografts and aims to improve patient outcomes through innovative products and scientific research.
MiMedx Group, Inc. (OTC PINK: MDXG) announced that its common stock will begin trading on The Nasdaq Stock Market from November 4, 2020. This move marks a significant milestone for the company, which specializes in advanced wound care and therapeutic biologics. MiMedx is recognized for its development and distribution of human placental tissue allografts using its proprietary PURION® process. The company has successfully supplied over two million allografts to the healthcare sector.
MiMedx Group (OTC PINK: MDXG) filed a definitive proxy statement with the SEC for its 2020 Annual Meeting of Shareholders, set for November 20, 2020, at 10:00 a.m. ET. Due to COVID-19 concerns, the meeting will be virtual. Shareholders as of October 7, 2020, can participate and vote. The proxy statement and voting information are being mailed out, with accessible copies on the SEC and MiMedx websites. MiMedx specializes in advanced wound care through human placental tissue allografts, having supplied over 1.9 million allografts to date.